Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UC Irvine UCSF
Dates
study started
completion around

Description

Summary

This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Details

Keywords

Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Carcinoma, Neoplasms, Renal Cell Carcinoma, Adavosertib

Eligibility

Locations

  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Orange California 92868 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • UCSF Medical Center-Mount Zion
    San Francisco California 94115 United States
  • UCSF Medical Center-Mission Bay
    San Francisco California 94158 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT03284385
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated